Market Currents
More from the ASCO Oncology conference: Array BioPharma (ARRY) says its MEK162 selective...
-
Monday, June 4, 2012, 4:56 PM ETMore from the ASCO Oncology conference: Array BioPharma (ARRY) says its MEK162 selective inhibitor shows promising clinical activity in Phase ll trial in patients with NRAS mutated melanoma. Shares +2.5% AH.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
